SLC5A2 and heart failure: Further RCTs have reinforced the effectiveness of SGLT2 inhibitors in reducing hospitalizations and improving cardiovascular outcomes associated with heart failure, demonstrating a direct therapeutic effect that is independent of their glucose-lowering properties.